Sinaps onarıcı hap yeni bir şizofreni tedavisi olarak insanlarda denenecek. Kayıp sinir hücresi bağlantılarını yenileyen günde bir kez kullanılan bir hap şizofreni tedavisi olarak test ediliyor.
www.spinogenix.com/spinogenix-a...
www.spinogenix.com/spinogenix-a...
Spinogenix Announces Launch of a Phase 2 Clinical Trial Evaluating SPG302 for the Treatment of Schizophrenia - Spinogenix
Press Release Spinogenix Announces Launch of a Phase 2 Clinical Trial Evaluating SPG302 for the Treatment of Schizophrenia Phase 2 trial is designed to evaluate the safety, efficacy, tolerability, and...
www.spinogenix.com
September 27, 2024 at 9:13 AM
Sinaps onarıcı hap yeni bir şizofreni tedavisi olarak insanlarda denenecek. Kayıp sinir hücresi bağlantılarını yenileyen günde bir kez kullanılan bir hap şizofreni tedavisi olarak test ediliyor.
www.spinogenix.com/spinogenix-a...
www.spinogenix.com/spinogenix-a...
SPG601, a treatment developed by L.A.-based company Spinogenix to restore synapse function in people with Fragile X syndrome, gets fast track designation
cincinnatichildrenshospitalmc.us.newsweaver.com/1m1vhmv4sc/5...
@cincyresearch.bsky.social
cincinnatichildrenshospitalmc.us.newsweaver.com/1m1vhmv4sc/5...
@cincyresearch.bsky.social
Fragile X Treatment Gets Fast Track Designation - Research Horizons
cincinnatichildrenshospitalmc.us.newsweaver.com
January 21, 2025 at 1:19 PM
SPG601, a treatment developed by L.A.-based company Spinogenix to restore synapse function in people with Fragile X syndrome, gets fast track designation
cincinnatichildrenshospitalmc.us.newsweaver.com/1m1vhmv4sc/5...
@cincyresearch.bsky.social
cincinnatichildrenshospitalmc.us.newsweaver.com/1m1vhmv4sc/5...
@cincyresearch.bsky.social
ALS'de çığır açan gelişme.
Sinaps yenileyici hap faz 2 insan deneylerine giriyor.
ALS tedavisi için günde bir kez kullanılan benzersiz bir hap, devam eden klinik deneyler için onaylandı.
www.spinogenix.com/spinogenix-a...
Sinaps yenileyici hap faz 2 insan deneylerine giriyor.
ALS tedavisi için günde bir kez kullanılan benzersiz bir hap, devam eden klinik deneyler için onaylandı.
www.spinogenix.com/spinogenix-a...
Spinogenix Announces FDA Clearance of IND Application for SPG302, a Novel Therapy for the Treatment of ALS - Spinogenix
Press Release Spinogenix Announces FDA Clearance of IND Application for SPG302, a Novel Therapy for the Treatment of ALS SPG302 is being developed as a once-a-day pill with the potential to regenerate...
www.spinogenix.com
May 30, 2024 at 6:36 AM
ALS'de çığır açan gelişme.
Sinaps yenileyici hap faz 2 insan deneylerine giriyor.
ALS tedavisi için günde bir kez kullanılan benzersiz bir hap, devam eden klinik deneyler için onaylandı.
www.spinogenix.com/spinogenix-a...
Sinaps yenileyici hap faz 2 insan deneylerine giriyor.
ALS tedavisi için günde bir kez kullanılan benzersiz bir hap, devam eden klinik deneyler için onaylandı.
www.spinogenix.com/spinogenix-a...
Okay, so they expected to see some change in brain activity from this new schizophrenia drug... but the fact that it's showing *specific* EEG improvements in the occipital (p=0.011) and temporal (p=0.008) regions is pretty cool.
Spinogenix Reports Early Improvements in Phase 2 Trial of Tazbentetol in Patients with Schizophrenia
Spinogenix announced interim results from its Phase 2 trial evaluating tazbentetol, a first-in-class investigational synaptic regenerative therapy for schizophrenia. The study showed early improvement
www.prnewswire.com
March 26, 2026 at 12:01 PM
Okay, so they expected to see some change in brain activity from this new schizophrenia drug... but the fact that it's showing *specific* EEG improvements in the occipital (p=0.011) and temporal (p=0.008) regions is pretty cool.
New Study Reveals Potential of Tazbentetol in Treating Diabetic Retinal Neuropathy and Preserving Vision#USA#Los_Angeles#Spinogenix#Diabetic_Retinopathy#Tazbentetol
New Study Reveals Potential of Tazbentetol in Treating Diabetic Retinal Neuropathy and Preserving Vision
Spinogenix's latest research showcases Tazbentetol's capacity to mitigate diabetic retinal neuropathy, highlighting its significance in vision preservation.
third-news.com
October 6, 2026 at 1:14 PM
New Study Reveals Potential of Tazbentetol in Treating Diabetic Retinal Neuropathy and Preserving Vision#USA#Los_Angeles#Spinogenix#Diabetic_Retinopathy#Tazbentetol
Spinogenix, iletişimi yeniden sağlamak için nöronlar arasındaki sinaps adı verilen boşlukları yenileyen, günde bir kez kullanılan benzersiz bir hap olan SPG302'yi geliştirdi
May 30, 2024 at 7:17 AM
Spinogenix, iletişimi yeniden sağlamak için nöronlar arasındaki sinaps adı verilen boşlukları yenileyen, günde bir kez kullanılan benzersiz bir hap olan SPG302'yi geliştirdi
New Expanded Access Program for ALS.
Spinogenix Announces FDA-Authorized Expanded Access Program for SPG302, the First Synaptic Regenerative Therapy to Treat ALS
www.prnewswire.com/il/news-rele...
Spinogenix Announces FDA-Authorized Expanded Access Program for SPG302, the First Synaptic Regenerative Therapy to Treat ALS
www.prnewswire.com/il/news-rele...
Spinogenix Announces FDA-Authorized Expanded Access Program for SPG302, the First Synaptic Regenerative Therapy to Treat ALS
/PRNewswire/ -- Spinogenix, Inc., a clinical-stage biopharmaceutical company pioneering first-in-class therapeutics that restore synapses to improve the lives...
www.prnewswire.com
May 6, 2025 at 10:00 PM
New Expanded Access Program for ALS.
Spinogenix Announces FDA-Authorized Expanded Access Program for SPG302, the First Synaptic Regenerative Therapy to Treat ALS
www.prnewswire.com/il/news-rele...
Spinogenix Announces FDA-Authorized Expanded Access Program for SPG302, the First Synaptic Regenerative Therapy to Treat ALS
www.prnewswire.com/il/news-rele...
Amiyotrofik lateral skleroz (ALS) hastalarında kaybolan sinir hücresi bağlantılarını geri kazandıran günde bir kez kullanılan hapın arkasındaki şirket Spinogenix, şimdi gözünü bu hapı başka bir zayıflatıcı hastalık için yeni bir tedavi sağlamak üzere kullanmaya dikti: Şizofreni
September 27, 2024 at 9:14 AM
Amiyotrofik lateral skleroz (ALS) hastalarında kaybolan sinir hücresi bağlantılarını geri kazandıran günde bir kez kullanılan hapın arkasındaki şirket Spinogenix, şimdi gözünü bu hapı başka bir zayıflatıcı hastalık için yeni bir tedavi sağlamak üzere kullanmaya dikti: Şizofreni
Spinogenix, iletişimi yeniden sağlamak için nöronlar arasındaki sinaps adı verilen boşlukları yenileyen, günde bir kez kullanılan benzersiz bir hap olan SPG302'yi geliştirdi
May 30, 2024 at 7:17 AM
Spinogenix, iletişimi yeniden sağlamak için nöronlar arasındaki sinaps adı verilen boşlukları yenileyen, günde bir kez kullanılan benzersiz bir hap olan SPG302'yi geliştirdi
Spinogenix's Codabakalner Receives WHO Approval As Nonproprietary Name for SPG601#USA#Los_Angeles#Spinogenix#SPG601#Codabakalner
Spinogenix's Codabakalner Receives WHO Approval As Nonproprietary Name for SPG601
Spinogenix announces that the WHO has approved 'codabakalner' as the nonproprietary name for SPG601, a therapy for Fragile X syndrome.
third-news.com
July 16, 2026 at 12:42 PM
Spinogenix's Codabakalner Receives WHO Approval As Nonproprietary Name for SPG601#USA#Los_Angeles#Spinogenix#SPG601#Codabakalner
Spinogenix Reports Positive Data on Alzheimer’s Patients Who Continued Treatment With Tazbentetol For Up To 84 Weeks
Tazbentetol, a First-in-Class, Oral Synaptic Regenerative Investigational Therapy, Demonstrated Favorable Safety Profile and Durable Therapeutic Benefits Clinical Case Study…
Tazbentetol, a First-in-Class, Oral Synaptic Regenerative Investigational Therapy, Demonstrated Favorable Safety Profile and Durable Therapeutic Benefits Clinical Case Study…
Spinogenix Reports Positive Data on Alzheimer’s Patients Who Continued Treatment With Tazbentetol For Up To 84 Weeks
Tazbentetol, a First-in-Class, Oral Synaptic Regenerative Investigational Therapy, Demonstrated Favorable Safety Profile and Durable Therapeutic Benefits Clinical Case Study Presented at AAIC Highlights Caregiver Report of Rapid Cognitive Improvement with Supporting Clinical Outcome...
news-area.com
July 15, 2026 at 5:58 AM
Spinogenix Reports Positive Data on Alzheimer’s Patients Who Continued Treatment With Tazbentetol For Up To 84 Weeks
Tazbentetol, a First-in-Class, Oral Synaptic Regenerative Investigational Therapy, Demonstrated Favorable Safety Profile and Durable Therapeutic Benefits Clinical Case Study…
Tazbentetol, a First-in-Class, Oral Synaptic Regenerative Investigational Therapy, Demonstrated Favorable Safety Profile and Durable Therapeutic Benefits Clinical Case Study…
Spinogenix Unveils Sustained Improvement in Alzheimer's Patients Using Tazbentetol Over 84 Weeks#USA#Los_Angeles#Spinogenix#Tazbentetol#Alzheimer'sDisease
Spinogenix Unveils Sustained Improvement in Alzheimer's Patients Using Tazbentetol Over 84 Weeks
Latest data reveals Spinogenix's Tazbentetol shows impressive long-term cognitive benefits for Alzheimer's patients after extended treatment.
third-news.com
July 14, 2026 at 6:07 PM
Spinogenix Unveils Sustained Improvement in Alzheimer's Patients Using Tazbentetol Over 84 Weeks#USA#Los_Angeles#Spinogenix#Tazbentetol#Alzheimer'sDisease
what are folks thinking of this www.spinogenix.com/spinogenix-a...
Spinogenix Announces Launch of a Phase 2 Clinical Trial Evaluating SPG302 for the Treatment of Schizophrenia - Spinogenix
Press Release Spinogenix Announces Launch of a Phase 2 Clinical Trial Evaluating SPG302 for the Treatment of Schizophrenia Phase 2 trial is designed to evaluate the safety, efficacy, tolerability, and...
www.spinogenix.com
January 10, 2025 at 2:47 AM
what are folks thinking of this www.spinogenix.com/spinogenix-a...
🗣️Christoph U. Correll, MD, ponente invitado #congresomcnp 2026 , comparte sus pensamientos sobre la actualización relacionada con SPG302: Spinogenix anunció la inscripción abierta para su ensayo de fase 2 de SPG302 para el tratamiento de personas con esquizofrenia
April 10, 2025 at 5:09 PM
🗣️Christoph U. Correll, MD, ponente invitado #congresomcnp 2026 , comparte sus pensamientos sobre la actualización relacionada con SPG302: Spinogenix anunció la inscripción abierta para su ensayo de fase 2 de SPG302 para el tratamiento de personas con esquizofrenia
Çağsı'nın bazı kritik, önemli olduğunu düşündüğü iletileri yeniden attığı çok doğrudur. Çünkü aşağılara doğru gezintiye çıkmadığınız için bazılarınız görmemiş olabilir.
Öncü sinaps yenileyici ALS hapı insan deneylerinin 2. aşamasına ulaştı.
www.spinogenix.com/spinogenix-a...
Öncü sinaps yenileyici ALS hapı insan deneylerinin 2. aşamasına ulaştı.
www.spinogenix.com/spinogenix-a...
May 30, 2024 at 1:42 PM
Çağsı'nın bazı kritik, önemli olduğunu düşündüğü iletileri yeniden attığı çok doğrudur. Çünkü aşağılara doğru gezintiye çıkmadığınız için bazılarınız görmemiş olabilir.
Öncü sinaps yenileyici ALS hapı insan deneylerinin 2. aşamasına ulaştı.
www.spinogenix.com/spinogenix-a...
Öncü sinaps yenileyici ALS hapı insan deneylerinin 2. aşamasına ulaştı.
www.spinogenix.com/spinogenix-a...
Spinogenix Welcomes Renowned Neurology Professor to Scientific Advisory Board for Alzheimer's Research#USA#Los_Angeles#Alzheimer's#Spinogenix#Steven_Arnold
Spinogenix Welcomes Renowned Neurology Professor to Scientific Advisory Board for Alzheimer's Research
Spinogenix, a clinical-stage biopharmaceutical firm, has appointed Dr. Steven E. Arnold to its Scientific Advisory Board, focusing on Alzheimer's strategies.
third-news.com
July 9, 2026 at 12:51 PM
Spinogenix Welcomes Renowned Neurology Professor to Scientific Advisory Board for Alzheimer's Research#USA#Los_Angeles#Alzheimer's#Spinogenix#Steven_Arnold
Spinogenix Enhances Scientific Advisory Board with Renowned Neuroscientist Professor Joseph T. Coyle#USA#Los_Angeles#Neuroscience#Spinogenix#Joseph_T._Coyle
Spinogenix Enhances Scientific Advisory Board with Renowned Neuroscientist Professor Joseph T. Coyle
Spinogenix, a biopharmaceutical company, announces the appointment of Professor Joseph T. Coyle to its Scientific Advisory Board, focusing on advancing treatments for schizophrenia.
third-news.com
July 2, 2026 at 12:38 PM
Spinogenix Enhances Scientific Advisory Board with Renowned Neuroscientist Professor Joseph T. Coyle#USA#Los_Angeles#Neuroscience#Spinogenix#Joseph_T._Coyle
Spinogenix Celebrates Dr. Craig Erickson with Major Autism Research Grant Announcement#United_States#Los_Angeles#Autism#Spinogenix#Craig_Erickson
Spinogenix Celebrates Dr. Craig Erickson with Major Autism Research Grant Announcement
Spinogenix, Inc. honors Dr. Craig Erickson and Cincinnati Children's Hospital for securing a $17.25 million autism research grant to enhance precision medicine.
third-news.com
June 15, 2026 at 12:38 PM
Spinogenix Celebrates Dr. Craig Erickson with Major Autism Research Grant Announcement#United_States#Los_Angeles#Autism#Spinogenix#Craig_Erickson
Spinogenix's Tazbentetol Earns Fast Track Designation for ALS Treatment Advancement#United_States#Los_Angeles#ALS#Spinogenix#Tazbentetol
Spinogenix's Tazbentetol Earns Fast Track Designation for ALS Treatment Advancement
Spinogenix has received a Fast Track Designation from the FDA for Tazbentetol, a pioneering treatment for ALS that shows promise in restoring synapse function.
third-news.com
May 5, 2026 at 1:35 PM
Spinogenix's Tazbentetol Earns Fast Track Designation for ALS Treatment Advancement#United_States#Los_Angeles#ALS#Spinogenix#Tazbentetol
Spinogenix Unveils Innovative Preclinical Findings on Tazbentetol for Treating Glaucoma and Diabetic Retinopathy#USA#Los_Angeles#Spinogenix#Tazbentetol#Neuroprotection
Spinogenix Unveils Innovative Preclinical Findings on Tazbentetol for Treating Glaucoma and Diabetic Retinopathy
Spinogenix is set to showcase groundbreaking preclinical research at ARVO 2026, demonstrating Tazbentetol's neuroprotective abilities in glaucoma and diabetic retinopathy models.
third-news.com
May 3, 2026 at 12:49 PM
Spinogenix Unveils Innovative Preclinical Findings on Tazbentetol for Treating Glaucoma and Diabetic Retinopathy#USA#Los_Angeles#Spinogenix#Tazbentetol#Neuroprotection
Spinogenix Initiates CLARITY Trial for SPG601 Targeting Fragile X Syndrome#United_States#Los_Angeles#Spinogenix#SPG601#Fragile_X
Spinogenix Initiates CLARITY Trial for SPG601 Targeting Fragile X Syndrome
Spinogenix, Inc. has launched the CLARITY trial for SPG601, an oral treatment for Fragile X Syndrome, aiming to restore synaptic function.
third-news.com
April 23, 2026 at 1:04 PM
Spinogenix Initiates CLARITY Trial for SPG601 Targeting Fragile X Syndrome#United_States#Los_Angeles#Spinogenix#SPG601#Fragile_X
New Research Highlights the Potential of SPG601 for Treating Fragile X Syndrome#United_States#Los_Angeles#Spinogenix#SPG601#Fragile_X
New Research Highlights the Potential of SPG601 for Treating Fragile X Syndrome
A recent peer-reviewed study shows that Spinogenix's SPG601 could effectively improve cognitive functions in patients with Fragile X Syndrome, marking a significant breakthrough in treatment.
third-news.com
April 9, 2026 at 12:52 PM
New Research Highlights the Potential of SPG601 for Treating Fragile X Syndrome#United_States#Los_Angeles#Spinogenix#SPG601#Fragile_X
Promising Results from Spinogenix's Phase 2 Trial of Tazbentetol for Schizophrenia Show Safety and Efficacy#United_States#Los_Angeles#schizophrenia#Spinogenix#Tazbentetol
Promising Results from Spinogenix's Phase 2 Trial of Tazbentetol for Schizophrenia Show Safety and Efficacy
Spinogenix's Phase 2 trial data reveals early improvements in treating schizophrenia with Tazbentetol, highlighting safety and symptom reduction.
third-news.com
March 26, 2026 at 11:14 AM
Promising Results from Spinogenix's Phase 2 Trial of Tazbentetol for Schizophrenia Show Safety and Efficacy#United_States#Los_Angeles#schizophrenia#Spinogenix#Tazbentetol